{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:12:11Z","timestamp":1789791131647,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Anti\u2013N-methyl-D-aspartate receptor (NMDAR) encephalitis is an auto-immune neurological disorder characterized by the presence in the cerebrospinal fluid (CSF) of antibodies against the GluN1 subunit of NMDA receptors in the brain. The etiology of the disease remains largely unknown. In this study, we aimed to investigate the possible existence of pharmacovigilance signals relating to a link between vaccination and the occurrence of anti-NMDAR encephalitis. We performed a case\/non-case study using data from the World Health Organization pharmacovigilance database (VigiBase) up to 31 December 2021. All individual case study reports (ICSRs) linked to a vaccine and coded with the MedDRA Lower Level Term (LLT) \u201canti-NMDA receptor encephalitis\u201d were analysed. We calculated the Reporting Odds Ratio (ROR) and 95% Confidence Interval (CI) for each type of vaccine. A total of 29,758,737 ICSRs were registered in VigiBase, of which 70 were coded under the selected LLT, and 29\/70 (41.4%) involved a vaccine. Of these cases, 53.8% involved children aged younger than 15\u00a0years. The median time to onset of anti-NMDAR encephalitis after vaccination was 4\u00a0days (range 0\u2013730). The highest RORs were observed for the diphtheria\/polio\/tetanus\/pertussis vaccine [54.72 (95% CI 26.2\u2013114.3)], yellow fever vaccine [50.02 (95% CI 15.7\u2013159)] and human papillomavirus vaccine [32.89 (15.8\u201368.7)]. All cases were coded as serious; 13 patients did not recover, or were left with permanent sequelae. Nine patients recovered without sequelae or are on the path to recovery, and one patient died. In summary, pharmacovigilance signals were observed for anti-NMDAR encephalitis and vaccination. Clinicians need to be aware of this potential risk, and encourage to report any case of anti-NMDAR encephalitis occurring after vaccination.<\/jats:p>","DOI":"10.3389\/fphar.2022.940780","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T08:20:19Z","timestamp":1660724419000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Salom\u00e9","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahim","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Trenque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/jpn.JPN_185_16","article-title":"Pediatric autoimmune encephalitis","volume":"12","author":"Barbagallo","year":"2017","journal-title":"J. Pediatr. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s12026-016-8855-1","article-title":"Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination","volume":"65","author":"Blitshteyn","year":"2017","journal-title":"Immunol. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmr.2018.02.015","article-title":"History and principles of vaccination","volume":"36","author":"Canou\u00ef","year":"2019","journal-title":"Rev. Mal. Respir."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2022.2033540","article-title":"Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse","volume":"18","author":"Etemadifar","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: Principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B10","doi-asserted-by":"publisher","first-page":"764197","DOI":"10.3389\/fneur.2021.764197","article-title":"Acute psychosis due to anti-N-methyl D-aspartate receptor encephalitis following COVID-19 vaccination: A case report","volume":"12","author":"Flannery","year":"2021","journal-title":"Front. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ana.21756","article-title":"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Ann. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.mayocp.2019.02.025","article-title":"Vaccines for international travel","volume":"94","author":"Freedman","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4103\/0366-6999.180514","article-title":"Autoimmune encephalitis: An expanding frontier of neuroimmunology","volume":"129","author":"Guan","year":"2016","journal-title":"Chin. Med. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"577548","DOI":"10.1016\/j.jneuroim.2021.577548","article-title":"Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases","volume":"355","author":"Guedes","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1080\/21645515.2015.1082014","article-title":"Vaccination of healthcare workers: A review","volume":"11","author":"Haviari","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00415-010-5757-3","article-title":"Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: Cause or coincidence?","volume":"258","author":"Hofmann","year":"2011","journal-title":"J. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-d-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40264-022-01151-w","article-title":"Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands","volume":"45","author":"Kant","year":"2022","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database: Commentary","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.15585\/mmwr.mm7043a1","article-title":"Routine vaccination coverage \u2014 worldwide","volume":"70","author":"Muhoza","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep. (MMWR)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.tmaid.2022.102278","article-title":"Travel vaccines throughout history","volume":"46","author":"Pavli","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","article-title":"Is reporting rate a good predictor of risks associated with drugs?","volume":"47","author":"Pierfitte","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/21645515.2020.1827882","article-title":"Who should be prioritised for COVID-19 vaccination?","volume":"17","author":"Russell","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/ijms18010193","article-title":"Anti-NMDA receptor encephalitis and vaccination","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10072-020-04482-7","article-title":"Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: A retrospective, multicenter, self-controlled study","volume":"42","author":"Zeng","year":"2021","journal-title":"Neurol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/ana.26182","article-title":"Postvaccinal encephalitis after ChAdOx1 nCov\u201019","volume":"90","author":"Zuhorn","year":"2021","journal-title":"Ann. Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.940780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T08:20:22Z","timestamp":1660724422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.940780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":26,"alternative-id":["10.3389\/fphar.2022.940780"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.940780","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"940780"}}